"id","name","description","label","text","uuid:ID","instanceType"
"Objective_1","OBJ1","Main objective","","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","544e3a04-224f-48c5-bf19-c5272d9ee616","Objective"
"Objective_2","OBJ2","Safety","","To document the safety profile of the xanomeline TTS.","7f0c8840-f63e-4aa3-a904-8c27332d615d","Objective"
"Objective_3","OBJ3","Behaviour","","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","d8308f77-c5c5-4f02-b20a-d0a5afe06a9b","Objective"
"Objective_4","OBJ4","","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","e58879da-4094-4583-b2c7-aa26bc079808","Objective"
"Objective_5","OBJ5","","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","13619106-8500-4c95-9a33-94ffaa9cac70","Objective"
"Objective_6","OBJ6","","","To assess the treatment response as a function of Apo E genotype.","45ac8cbc-22b2-4a57-8932-d83415710323","Objective"
